Crescent Biopharma, Inc.CBIONASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+51.0%
5Y CAGR+21.5%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+51.0%/yr
vs -2.0%/yr prior
5Y CAGR
+21.5%/yr
Recent acceleration
Acceleration
+53.0pp
Accelerating
Percentile
P100
Near historical high
vs 5Y Ago
2.6x
Strong expansion
Streak
2 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$163.39M+137.6%
2024$68.76M+75.0%
2023$39.29M-17.3%
2022$47.48M-26.5%
2021$64.61M+4.8%
2020$61.67M+0.5%
2019$61.39M+19.2%
2018$51.51M+53.0%
2017$33.67M+5.4%
2016$31.93M-